Elevance Health Stock News

My Top 15 high-growth dividend stocks for September 2025 are collectively 32% undervalued and offer a 1.43% yield with 21.57% five-year dividend growth. The strategy's five-year annualized return is 11.22%, just shy of my 12% target, but it continues to outperform VIG and SPY year-to-date. Rotation in the list brings in DICK'S Sporting Goods, Elevance Health, Intuit, and Marsh & McLennan, repla...

Elevance and peers face earnings pressure from rising medical costs, driven by deferred care, expensive drugs, and persistent medical inflation. The segment has re-rated, and now offers good value. Investor sentiment has returned, and capital is rotating into healthcare.

A federal judge in Texas on Tuesday rejected Elevance Health's challenge of the U.S. government's calculation for the health insurer's star ratings for some of its government-backed Medicare plans after the company said improper rounding cost it at least $375 million.

INDIANAPOLIS--(BUSINESS WIRE)-- #ElevanceHealth--Elevance Health and the National Association of Community Health Centers (NACHC) are proud to announce the integration of Food as Medicine (FAM) programming with primary care Community Health Centers (CHCs). This milestone - built on a shared commitment to whole health and community-centered innovation - marks a transformative step forward in add...

These stocks have high upside potential through 2027. They're sitting at solid discounts and have good fundamentals.

Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a lineup of blockbuster drugs and a solid pipeline of drugs, an A S&P credit rating, and offers a safe and sizable yield. Rexford Industrial Realty owns high-value, mission-critical real estate, pays a...

Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses, guidance cuts, and Medicare Advantage mispricing, despite its long-term potential to restore profitability. Thermo Fisher and argenx detracted from performance amid macro headwinds and lower-than...

INDIANAPOLIS--(BUSINESS WIRE)--The board of directors of Elevance Health (NYSE: ELV) announced today that Steve Collis, a highly regarded global healthcare executive, will be joining the company's board, effective August 1. He will also serve on the board's Audit and Finance Committees, further enhancing the board's industry expertise and financial oversight capabilities. His addition is part o...